Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
mannan/càncer de mama
L'enllaç es desa al porta-retalls
Pàgina 1 des de 21 resultats
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
Mucin 1 (MUC1) is a high molecular weight glycoprotein overexpressed on adenocarcinoma cells and is a target for immunotherapy protocols. To date, clinical trials against MUC1 have included advanced cancer patients. Herein, we report a trial using early stage breast cancer patients and
Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
Targeting antigens to dendritic cell receptors has recently become a popular approach to inducing effective immune responses against cancer antigens. Almost 20 years ago, however, we demonstrated that targeting the mannose receptor on macrophages and dendritic cells leads to strong
Cell-mediated immune responses to MUC1 fusion protein coupled to mannan.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The immunotherapy of cancer requires the definition of a suitable target for and the induction of a CD8+ cytotoxic lymphocyte reaction. In breast cancer, particularly mucins (MUC1) of the variable number of tandem repeat sequence may be a suitable target, but there has been a problem in inducing a
Mannan-binding lectin and healing of a radiation-induced chronic ulcer--a case report on mannan-binding lectin replacement therapy.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Mannan-binding lectin is an important component of innate immunity, and insufficiency is associated with several clinical disorders. Recently, experimental replacement therapy with plasma-derived mannan-binding lectin has become an option. The current article presents the case of a patient with an
The effect of T1 and T2 cytokines on the cytotoxic T cell response to mannan-MUC1.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
MUC1 is a mucin over-expressed in breast cancer and a proposed target for immunotherapy. By immunising mice with MUC1 conjugated to mannan (M-FP), CD8(+) MHC-class-I restricted cytotoxic T lymphocytes (CTL), of high CTL precursor (CTLp) frequency (1/8000) and with significant tumour protection, can
Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
HLA-A*0201/Kb transgenic mice were immunized with oxidized mannan-mucin 1 (MUC1) as a fusion protein (containing five repeats of the 20-amino-acid MUC1 VNTR (variable number of tandem repeats) that generated highly active CD8+ CTLs to MUC1 peptides. In a direct CTL assay, the MUC1 peptides could be
Cyclophosphamide enhances the CTL precursor frequency in mice immunized with MUC1-mannan fusion protein (M-FP).
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
We have previously described the induction of murine CD8+ major histocompatibility complex class I restricted cytotoxic T cells to the 20 amino acid repeat region of human Mucin 1 (MUC1) variable number of tandem repeats region--a mucin greatly increased in expression in breast cancer and proposed
Breast cancer in mice: effect of murine MUC-1 immunization on tumor incidence in C3H/HeOuj mice.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Mucin-1 (MUC-1), which is overexpressed in more than 90% of human breast cancers, is a potential target for immunotherapy. To develop a mouse model appropriate for the immunotherapy of human cancer, mouse mucin-1 (muc-1) fusion protein, containing ten tandem repeats, was made and used to immunize
Breast cancer immunotherapy: current status and future prospects.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The development of an immunotherapeutic approach to cancer is the concern for many immunologists, but despite the impressive progress over the past decade, such as the identification of tumour antigens and antigenic peptides as potential targets, there are still many obstacles in eliciting an
Mucin based breast cancer vaccines.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Of the 8 human epithelial mucins identified so far, MUC1 has been the focus of attention for immunotherapeutic applications. The gene MUC1 encodes a large membrane associated glycoprotein where the majority of the extracellular domain is made up of tandem repeats of 20 amino acids. In breast cancer
Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The mucin MUC1 is greatly increased in breast cancer and is a potential target for immunotherapy. In mice, MUCI conjugated to oxidized mannan (MUC1-mannan fusion protein [M-FP]) targets the mannose receptor and induces a high frequency of cytotoxic T lymphocytes and anti-tumor responses. On this
Mannan Mucin-1 Peptide Immunization: Influence of Cyclophosphamide and the Route of Injection.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
SUMMARY: The mucin MUC1 is greatly increased in breast cancer and is a potential target for immunotherapy. In mice, MUC1 conjugated to oxidized mannan (MUC1-mannan fusion protein [M-FP]) targets the mannose receptor and induces a high frequency of cytotoxic T lymphocytes and anti-tumor responses. On
MUC1 and breast cancer.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The development of an effective immunotherapeutic approach to cancer is now a major focus of research, and despite impressive progress over the last 10 years there are still many hurdles to overcome to elicit an effective immune response which will totally eradicate the cancer. Mucins (MUC1) have
Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Mucin 1 (MUC1) is a large complex glycoprotein that is highly expressed in breast cancer, and as such could be a target for immunotherapy. In mice, human MUC1 is highly immunogenic, particularly when conjugated to mannan, where a high frequency of CD8(+) MHC-restricted cytotoxic T lymphocytes is
Hepatic clearance and metabolism in the rat of a human breast cancer associated glycoprotein (GCDFP-15).
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Gross Cystic Disease Fluid Protein (GCDFP-15) is a 60,000 dalton glycoprotein isolated from human breast cyst fluid, composed of four 15,000 dalton monomers. Carbohydrate analysis indicates that each monomer has a single carbohydrate chain of the complex type. GCDFP-15 intravenously injected into
La base de dades d’herbes medicinals més completa avalada per la ciència
- Funciona en 55 idiomes
- Cures a base d'herbes recolzades per la ciència
- Reconeixement d’herbes per imatge
- Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
- Llegiu publicacions científiques relacionades amb la vostra cerca
- Cerqueu herbes medicinals pels seus efectes
- Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents
Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades
